Groups

Here we go again! Subtyping diagnosis and refining treatments

Javier Vázquez-Bourgon
Rev Psiquiatr Salud Ment. 2022;15:221-2

Texto completo - PDF

Risk factors of deficit and non-deficit schizophrenia: Results from a cross-sectional study

Agnieszka Cyran, Patryk Piotrowski, Jerzy Samochowiec, Tomasz Grąźlewski, Błażej Misiak
Rev Psiquiatr Salud Ment. 2022;15:223-9

Resumen - Texto completo - PDF

Dried Blood Spot (DBS) as a useful tool to improve clozapine, aripiprazole and paliperidone treatment: From adherence to efficiency

Miguel Bernardo, Gisela Mezquida, Paula Ferré, Bibiana Cabrera, Mercè Torra, Ana Maria Lizana, Mercè Brunet
Rev Psiquiatr Salud Ment. 2022;15:230-7

Resumen - Texto completo - PDF

Clozapine-associated myocarditis in the World Health Organization's pharmacovigilance database: Focus on reports from various countries

Carlos De las Cuevas, Emilio J. Sanz, Can-Jun Ruan, Jose de Leon
Rev Psiquiatr Salud Ment. 2022;15:238-50

Resumen - Texto completo - PDF

Clinical symptoms and social functioning in schizophrenia

Maria Jose Escandell, Gemma Prat, Mar Garcia-Franco, Jose Ramón Martín-Martínez, Susana Ochoa, Ingrid Tortades, Sonia Vilamala, Marina Verdaguer-Rodríguez, Emma Casas-Anguera
Rev Psiquiatr Salud Ment. 2022;15:251-8

Resumen - Texto completo - PDF

Salud mental